1 Strips of human saphenous veins and of human renal arteries and veins were superfused with KrebsHenseleit solution at 37°C. Constrictor responses were elicited by exogenous noradrenaline and the P2X-purinoceptor-selective agonist, ,'y-methylene-L-ATP.
Introduction
P2x-purinoceptors on blood vessels mediate vasoconstrictor responses to exogenous ATP and ATP analogues as well as to endogenous ATP released as a sympathetic cotransmitter (for review see Burnstock, 1990; Kennedy, 1990; Olsson & Pearson, 1990 ; Ralevic & Burnstock, 1991; Klgelgen & Starke, 1991; Abbracchio & Burnstock, 1994) . This extends to the rat kidney where ATP is involved as a sympathetic cotransmitter in nerve stimulation-induced vasoconstriction (Schwartz & Malik, 1989; Rump et al., 1990; Bohmann et al., 1995;  for a controversial finding see Sehic et al., 1994) . Vasoconstriction-mediating P2x-purinoceptors also operate on human subcutaneous, omental, skeletal muscle, pulmonary and pial arteries (Hardebo et al., 1987; Pernow et al., 1987; Liu et al., 1989; Martin et al., 1991) as well as on human mesenteric, saphenous and ovarian veins (Pernow et al., 1987; KiUgelgen, 1994; Stones et al., 1994) . However, to our knowledge no information concerning P2x-purinoceptormediated effects on blood vessels of the human kidney is available. Therefore, we analyzed the effects of the metabolically stable and P2x-purinoceptor-selective agonist, P,y-methylene-L-ATP (Hourani et al., 1985; 1986; Leffet al., 1990 ; see also von Klgelgen et al., 1995) on human renal blood vessels and saphenous veins. In order to characterize the receptor mediating the responses to P,y-methylene-L-ATP we also stuAuthor for correspondence. died in saphenous veins the interaction with the non-subtype selective P2-purinoceptor antagonist, suramin (Dunn & Blakely, 1988; von Kugelgen et al., 1989; Hoyle et al., 1990; Leff et al., 1990 ) and the P2X-preferential P2-purinoceptor antagonist, pyridoxal -phosphate -6 -azophenyl -2',4'-disulphonic acid (PPADS; Lambrecht et al., 1992; Windscheif et al., 1994; Ziganshin et al., 1994 The strips were mounted in a jacketed chamber maintained at 370C and superfused with Krebs-Henseleit solution at a constant rate of 6 ml min-'. The superfusion fluid was gassed continuously with carbogen (95% 02/5% C02) and passed through a heat exchanger (370C) before it reached the vessels. The strips were connected to a force-displacement transducer (Biegestab K30, Hugo Sachs Electronics, March-Hugstetten, Germany) for measuring isometric tension with a multi-pen recorder (Rikadenki, Freiburg i. Br., Germany). Initial tension was set at 19.6 mN; during the first 60 (veins) or 90 min (arteries) of superfusion, the tissues relaxed to approximately 7 mN. After this equilibration period, vasoconstrictor responses were elicited by addition of noradrenaline or j,Y-methylene-L-ATP to the superfusion solution at increasing concentrations in a cumulative manner (see also Leff et al., 1990) . For interaction experiments with purinoceptor antagonists or their solvent (water), a second concentration-response curve for an agonist was performed on the same preparation after an interval of 60 min. Antagonists or their solvent were added to the medium immediately after the first concentrationresponse curve.
Vasoconstrictor responses were measured as the maximum increase in tension (mN) above resting tension. Responses in the second concentration-response curve (saphenous veins) were expressed as a percentage of the maximal response obtained in the first concentration-response curve. Where relevant, the sigmoid-shaped function No. 25 of Waud (1976) was fitted to averaged agonist concentration-response data. The function yielded the maximal constrictor response and the EC50 (concentration that caused 50% of the maximal response). For estimation of the affinity constant of suramin at the P2x-purinoceptor in saphenous veins, an apparent pKB(-log KB) value of suramin was calculated from the shift of the concentration-response curve read at the level of 50% of the maximal response according to equation No. 4 of Furchgott (1972) . Since only one antagonist concentration was used for calculation and a competitive character of the antagonism was not verified, the value is an apparent pKB value (cf. von Kugelgen et al., 1995) .
Further experimental details are given in the Results section. J,y-methylene-L-ATP to the right (V in Figure 3a) . From the shift at the level of 50% of the maximal response, an apparent pKB value of suramin against P,y-methylene-L-ATP of 4.8 was calculated (equation No. 4 of Furchgott, 1972) . At a concentration of 100 gM, suramin very markedly inhibited responses to Py-methylene-L-ATP (A in Figure 3a) . The P2x-preferential antagonist PPADS used at a concentration of 3 gM slightly reduced the responses to P,y-methylene-L-ATP (* in Figure 3b ). At a ten times higher concentration (30 gM)
PPADS very markedly inhibited the responses to P,y-methylene-L-ATP with an obvious reduction in the maximal response (-in Figure 3b ). In contrast, PPADS (30 gM) caused no significant change in the concentration-response curve of noradrenaline (Figure 4 ).
Renal blood vessels
Responses to noradrenaline and J,y-methylene-L-ATP in saphenous veins were compared to responses to these agonists in renal blood vessels. In human saphenous veins, f,y-methylene-L-ATP elicited marked constrictor responses as previously demonstrated in this tissue for the ATP analogue occ-methylene-ATP (Rump & von Kilgelgen, 1994) . The interaction with the P2-purinoceptor antagonists, suramin and PPADS indicate that the constrictor responses to fy-methylene-L-ATP are mediated by the P2X-subtype of P2-purinoceptor. Suramin has recently been shown to inhibit the constrictor responses to aj-methylene-ATP in human saphenous veins without changing the responses to exogenous noradrenaline (Rump & von Kigelgen, 1994) . Noradrenaline (gM) Figure 4 Interaction of pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) with noradrenaline in human saphenous veins. Hoyle et al., 1990; Leff et al., 1990; von Kiigelgen et al., 1990) . Moreover, the preferential P2x-purinoceptor antagonist, PPADS (30 gM) markedly reduced the responses of human saphenous veins to j,y-methylene-L-ATP while causing no change in the response to noradrenaline. PPADS is known to cause a selective, but non-competitive interaction with the P2x-purinoceptor in rat and rabbit vascular tissues (Windscheif et al., 1994; Ziganshin et al., 1994) . The reduction of the maximal response to P,y-methylene-L-ATP by PPADS (30 gM) in human saphenous veins also indicates a non-competitive character of the interaction of PPADS with the P2x-purinoceptor in human tissues. In human renal blood vessels, 3,y-methylene-L-ATP caused almost no or only small constrictor responses despite the fact that the responses to noradrenaline were quite similar in all human blood vessels tested. This suggests tissue differences in the occurrence or operation of P2x-purinoceptors in human vascular tissues. In line with regional differences in constrictor responsiveness of blood vessel in the kidney to activation of P2x-purinoceptors (for rat kidney see Inscho et al., 1994) Iymethylene-L-ATP caused some responses in intrarenal arteries but almost no responses in extrarenal arteries as well as veins.
In conclusion, this study demonstrates that the P2x-purinoceptor agonist 0,,y-methylene-L-ATP induces marked constrictor responses in the human saphenous vein while causing almost no or only moderate responses in renal blood vessels.
This tissue difference in responsiveness to a P2x-purinoceptor agonist may be important for the clinical use of related drugs.
Thus, P2X-purinoceptor agonists may increase renal blod flow (see also Harvey, 1964) due to an enhanced systemic blood pressure in the absence of an altered renal vascular resistance. Moreover, the results indicate that PPADS blocks vasoconstriction-mediating P2x-purinoceptors in human blood vessels as previously demonstrated in rat and rabbit vascular tissues (Windscheif et al., 1994; Ziganshin et al., 1994) .
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